Corporate History
| April 2001 |
Established in Shiba, Minato-ku, Tokyo to contribute to research and development of anti-cancer medicine, cancer therapy and cancer diagnosis based on cancer-related genes and proteins. |
| May 2001 |
Commenced collaboration with the Institute of Medical Science, University of Tokyo. |
| November 2001 |
Moved to Shirokanedai, Minato-ku, Tokyo. |
| October 2002 |
Opened research laboratory in Minato-ku, Tokyo. |
| December 2003 |
Listed on the Mothers Market of the Tokyo Stock Exchange. |
| August 2004 |
Established Immunas Pharma, Inc., a joint venture with MBL. |
| March 2005 |
Head office and research laboratory moved to Takatsu-ku, Kawasaki city, Kanagawa prefecture. |
| June 2006 |
Established Vaccine Science Inc., a consolidated subsidiary company of OTS. (Merged in September 2007) |
| September 2007 |
Immunas Pharma, Inc. became a consolidated subsidiary of OTS. (Merged in March 2024) |
| May 2010 |
Established Laboratoires OncoTherapy Science France S.A.R.L., a consolidated subsidiary of OTS. (Liquidated in September 2019) |
| July 2017 |
Established Cancer Precision Medicine, Inc., a consolidated subsidiary of OTS. |
| August 2017 |
Cancer Precision Medicine, Inc. changed into a joint venture with OTS and Theragen Bio Co., Ltd.. |
| November 2017 |
Split Tumor Immunology Dept. from OTS to Cancer Precision Medicine, Inc.. |
| April 2022 |
Transition to the Growth Market of the Tokyo Stock Exchange. |
| January 2023 |
Head office and research laboratory moved to Kawasaki-ku, Kawasaki city, Kanagawa prefecture. |